***BMC Pharmacology and Toxicology***

**Additional file 2**

**Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects**

Yoshiaki Kirigaya1, Masanari Shiramoto2,Tomoko Ishizuka1, Hinako Uchimaru2, Shin Irie2, Manabu Kato1, Takako Shimizu1, Takafumi Nakatsu1, Yasuhiro Nishikawa1and Hitoshi Ishizuka1

1Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

2SOUSEIKAI Hakata Clinic, 6-18, Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan.

**Corresponding author:**

Yoshiaki Kirigaya

Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Telephone: +81-8010136896

Fax: +81-357403625

Email: kirigaya.yoshiaki.c8@daiichisankyo.co.jp

***Supplementary Table S1.*** *Summary of adverse events*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Adverse event** | **Study 1** | | **Study 2** | | **Study 3** | |
| **Esaxerenone 2.5 mg** | | **Amlodipine 2.5 mg** | | **Digoxin 0.25 mg/day** | |
| **Alone (n=24)** | **+ Amlodipine**  **10 mg/day (n=22a)** | **Alone (n=20)** | **+ Esaxerenone**  **5 mg/day (n=18a)** | **Alone (n=20)** | **+ Esaxerenone 5 mg/day (n=19a)** |
|
| Any TEAE | 1 (4.2) | 1 (4.5) | 1 (5.0) | 0 | 2 (10.0) | 0 |
| Gastroenteritis | 1 (4.2) | 0 | 0 | 0 | 0 | 0 |
| Tonsillitis | 0 | 0 | 1 (5.0) | 0 | 0 | 0 |
| Nasopharyngitis | 0 | 0 | 0 | 0 | 1 (5.0) | 0 |
| Loss of appetite | 1 (4.2) | 0 | 0 | 0 | 0 | 0 |
| Muscle cramp | 0 | 1 (4.5) | 0 | 0 | 0 | 0 |
| Increased alanine aminotransferase | 0 | 0 | 0 | 0 | 1 (5.0) | 0 |
| Increased aspartate aminotransferase | 0 | 0 | 0 | 0 | 1 (5.0) | 0 |
| Increased blood creatine phosphokinase | 0 | 1 (4.5) | 0 | 0 | 0 | 0 |

Values are number of subjects (%).

aSubjects who were withdrawn were not included in this analysis.

TEAE, treatment-emergent adverse event.